Researchers at the University of Georgia and Sanofi Pasteur, the vaccines division of Sanofi, announced today the development of a vaccine that protects against multiple strains of both seasonal and pandemic H1N1 influenza in mouse models.
They published their findings recently in the Journal of Virology.
Researchers from UGA and Sanofi Pasteur, which has a research and development collaboration agreement with UGA, will present their data tomorrow, March 30, at the World Vaccine Congress US 2016 in Washington, D.C.
“One of the problems with current influenza vaccines is that we have to make predictions about which virus strains will be most prevalent every year and build our vaccines around those predictions,” said Ted Ross, director of UGA’s Center for Vaccines and Immunology and Georgia Research Alliance Eminent Scholar in Infectious Diseases in the College of Veterinary Medicine. “What we have developed is a vaccine that protects against multiple different strains of H1N1 virus at once, so we might be able to one day replace the current standard of care with this more broadly cross-protective vaccine.”
The H1N1 influenza virus caused a worldwide pandemic in 2009. When it was first detected, it was called swine flu because the virus was similar to those found in pigs, but the virus now circulates as a seasonal form of influenza.
Using a technique called Computationally Optimized Broadly Reactive Antigen, or COBRA, UGA researchers Donald Carter, Christopher Darby and Bradford Lefoley, along with Ross, created nine prototype synthetic compound vaccines constructed using genetic sequences from multiple influenza virus strains.
The COBRA vaccines were designed to recognize H1N1 viruses isolated within the last 100 years, but many of the experimental vaccines produced immunity against influenza strains not included in the design. This means that scientists may be able to produce a vaccine that not only protects against recognized seasonal and pandemic influenza strains, but also strains that have yet to be discovered.
Because this vaccine is generated from the genetic sequences of multiple flu viruses, it may protect against many strains over several years, Ross said. That would also allow for year-round manufacturing of the vaccine, since scientists would not have to halt production every year to identify the most prevalent strains.
This research is part of a broader effort to create a universal influenza vaccine, which would protect against all strains of the virus.
“We still have some work to do before we get a truly universal flu vaccine,” Ross said. “But the COBRA vaccine we’ve developed for H1N1 virus subtypes is a major step in the right direction.”
Learn more: UGA, Sanofi Pasteur develop new vaccine for H1N1 influenza
The Latest on: Flu vaccine
[google_news title=”” keyword=”flu vaccine” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Flu vaccine
- Nick Jonas shares he has ‘nasty strain of influenza A’, apologises to fans for not being able to perform. Watchon May 3, 2024 at 6:57 pm
Nick Jonas said he has "fever, body ache, sore throat and really bad cough". He added that after the doctor did a checkup, his health hadn't "gotten better." ...
- Neurologic Disorders More Likely After Influenza vs COVID-19 Hospitalizationon May 3, 2024 at 7:01 am
In a retrospective cohort study, researchers used health care claims data to compare subsequent neurologic diagnoses in patients hospitalized with COVID-19 with those hospitalized with influenza.
- Launching an effective bird flu vaccine quickly could be tough, scientists warnon May 3, 2024 at 6:00 am
Federal health officials say the U.S. has the building blocks to make a vaccine to protect humans from bird flu, if needed. But experts warn we're nowhere near prepared for another pandemic.
- What’s Going Around: Seasonal allergies, strep throat, influenza, stomach viruses, COVIDon May 2, 2024 at 6:22 pm
Here’s our weekly round-up of what illnesses are spreading the most in Metro Detroit communities, according to our local doctors and hospitals.
- USDA addresses studies evaluating avian influenza in beefon May 2, 2024 at 1:00 pm
To verify the safety of the meat supply in the context of H5N1, the USDA’s FSIS, APHIS, and Agricultural Research Service (ARS) are working on three separate beef safety studies related to avian ...
- New vaccine approach shows promise in targeting less variable region of influenza viruson May 2, 2024 at 12:53 pm
Duke researchers have opened a new avenue in the attack against influenza viruses by creating a vaccine that encourages the immune system to target a portion of the virus surface that is less variable ...
- No More Yearly Flu Shots? Vaccine Mixed From 80,000 Proteins Could Be The Keyon May 2, 2024 at 7:45 am
So far, it’s worked well in mice and ferrets – could we soon be looking at a human equivalent? Why do we need to get a flu vaccine every year? Seasonal flu is responsible for roughly half a million ...
- CSL : Real-World Evidence Study Proves Effectiveness Of Cell-Based Quadrivalent Influenza Vaccineson May 2, 2024 at 7:42 am
(RTTNews) - CSL Seqirus, a subsidiary of CSL Ltd. (CSL.AX), Thursday said that a real-world evidence study shows that a cell-based quadrivalent influenza vaccine has been more effective than an ...
- Influenza Newson May 1, 2024 at 5:00 pm
Mar. 1, 2024 — Researchers have identified antibodies targeting a hard-to-spot region of the influenza virus, shedding light on the relatively unexplored 'dark side' of the neuraminidase (NA ...
- Universal Flu Vaccine May No Longer Be a Long Shoton May 1, 2024 at 5:00 pm
The search for a universal flu vaccine has been long and fraught with false starts and dead ends. For more than five years, Nicholas Heaton, PhD, associate professor of molecular genetics and ...
via Bing News